Vistagen Therapeutics, Inc. Common Stock (VTGN) News

Latest headlines that mention VTGN, newest first · each headline opens the original publisher

VTGN quote

Last price: $0.17
Day change: -3.28%
Next earnings: 2026-11-12

Quote & chart Expected move Insider trading IV rank history

VTGN headlines

latest coverage

Not much coverage yet. VTGN has appeared in only a few headlines lately; new stories show up here as publishers cover it.

Seeking Alpha 2mo ago

VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M

Earnings T2VTGN

Yahoo Finance 2mo ago

SRX Global Acquires Stake in Vistagen Therapeutics

M&A T2SRXH VTGN

Yahoo Finance 3mo ago

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?

General T2VTGN

Seeking Alpha News 3mo ago

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

General T2VTGN

Investing.com 5mo ago

Vistagen reports preliminary data from social anxiety trial

General T3VTGN

VTGN news alerts

Get an alert by email or push when a new headline mentions VTGN.

More news

News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.